Suicidal Planning Among Americans 50 and Older Tripled in Four Years

The share of Americans aged 50 and older who reported suicidal ideation rose from 2.0 percent in 2021 to 2.9 percent in 2024, and the share who reported making a suicide plan nearly quadrupled, from 0.3 percent to 1.1 percent, according to an analysis of federal survey data published online October 21 in the Journal of Affective Disorders. Suicide attempts in the same group tripled, from 0.2 percent to 0.6 percent.

The study drew on the National Survey on Drug Use and Health, a nationally representative survey, and pooled 42,440 respondents aged 50 and over across the 2021 through 2024 waves. Kevin H. Yang, a psychiatrist at the University of California San Diego School of Medicine and the National Clinician Scholars Program at UCLA, led the work with colleagues at UCSD and Joseph J. Palamar of NYU Grossman School of Medicine.

Small absolute numbers, a consistent direction

Three percent of a population still reads as a low figure, and it is worth being precise about what changed. Ideation rose about 45 percent in relative terms; planning and attempts roughly tripled. All three trends were statistically significant at conventional thresholds — p = 0.049 for ideation, p < 0.001 for planning, p = 0.02 for attempts.

The planning number is the one clinicians tend to watch, because a plan is what separates a passive wish from an actionable risk. On the survey's arithmetic, the proportion of adults 50 and older who had made a plan in the past year went from roughly one in 333 to roughly one in 91.

The increase landed where screening does not look

The paper's most consequential finding is not the overall trend but where it came from. Significant increases in both ideation and planning were concentrated among people who did not meet criteria for a past-year major depressive episode. Ideation also rose among people without serious psychological distress, without past-year alcohol use and without prescription medication misuse.

That inverts the logic most screening frameworks run on. A clinic that flags suicide risk only after a positive depression screen, or only in patients it already considers high-risk, would have missed the group driving most of the increase. The authors put it plainly in their conclusion: the results "highlight potential gaps in prevention frameworks that rely exclusively on traditional risk factor screening and underscore the need for broader risk assessment in this population."

The absolute risk stayed higher in the groups with depression and other established risk factors. What changed was the trend, and trends are what prevention planning is built on.

Cannabis users saw the steepest rise in planning

The analysis tested whether the trends differed across subgroups, and one interaction stood out. Suicide planning rose 449.9 percent among adults 50 and older who used cannabis, against 188.3 percent among those who did not, an interaction the authors report at p = 0.04.

The finding is exploratory — a serial cross-sectional survey cannot establish whether cannabis use contributed to the rise, whether people at higher risk were more likely to use cannabis, or whether both moved with something else. The authors treat the study as exploratory throughout, and the subgroups, while drawn from a large pooled sample, still carry wide confidence intervals at these low base rates.

Why 50-plus is its own problem

The paper opens on the reason the age cutoff matters: suicide rates among middle-aged and older adults in the United States remain disproportionately high, a pattern that has outlasted several rounds of national prevention strategy. The study's own contribution is the trend line inside that population, which the authors describe as poorly characterized until now.

The clinical difficulty is that the same age group reaches mental health care through narrow doors. Someone in his fifties drinking heavily after a divorce may present in primary care with insomnia and hypertension, not with a psychiatric complaint. Chronic pain and prescribed opioids or benzodiazepines add another layer: dual diagnosis care exists precisely for the patient whose depression and substance use arrived together and need to be treated together.

Clinical guidance for older adults with depression does not differ in kind from guidance for younger adults — psychotherapy, medication, or both — but the practical constraints do: renal dosing, interactions with an existing medication list, and the fact that this population is more likely to be seen outside specialty mental health care. That is the argument for depression treatment being handled inside primary care rather than handed off, and for asking about suicidal thinking in the same visit.

What broader assessment would look like

The study does not test an intervention, so it cannot say which screening change would work. It does narrow the field. If the increase is concentrated among people without a depression diagnosis, then a tool that only follows a positive depression screen will keep missing them, and the alternative is asking about suicidal thinking directly — in primary care, in specialty visits for chronic conditions, and at discharge from an emergency department, which is where many older adults make their only contact with the health system in a given year.

The comparison worth keeping in view is with the overdose side of the same epidemic, where naloxone distribution and medication for opioid use disorder gave clinicians something concrete to hand a patient in crisis. Mental health has 988 and safety planning, both of which work better than nothing and neither of which reaches a man who has not told anyone he is thinking about it.

The next NSDUH release will show whether 2024's planning rate was a spike or the new floor. Four years of a consistent upward line, in a population that is growing as a share of the country, is the kind of signal that usually gets acted on only after it has been flat for a decade.